Impact of maintenance therapy using a half dose of the bacillus Calmette–Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Impact of maintenance therapy using a half dose of the bacillus Calmette–Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study ; volume:20 ; number:1 ; day:9 ; month:12 ; year:2020 ; pages:1-8 ; date:12.2020
BMC urology ; 20, Heft 1 (9.12.2020), 1-8, 12.2020
- Urheber
-
Koguchi, Dai
Matsumoto, Kazumasa
Hirayama, Takahiro
Moroo, Shigetaka
Kobayashi, Momoko
Katsumata, Hiroki
Ikeda, Masaomi
Iwamura, Masatsugu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12894-020-00766-4
- URN
-
urn:nbn:de:101:1-2021011715430787843558
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Koguchi, Dai
- Matsumoto, Kazumasa
- Hirayama, Takahiro
- Moroo, Shigetaka
- Kobayashi, Momoko
- Katsumata, Hiroki
- Ikeda, Masaomi
- Iwamura, Masatsugu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo
Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Post-Bacille Calmette–Guerin surveillance for non-muscle invasive bladder cancer: do random biopsies offer an advantage?
Durch Bacillus Calmette-Guerin induzierte Tuberkulose
Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Bacille Calmette-Guérin Supply Disruption Emphasizes the Importance of Stewardship
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Bekämpfung der Tuberkulose: Schutzimpfung mit Bacillus Calmette-Guérin (BCG)
Immunologic aspects of patients with disseminated bacille Calmette-Guerin disease in north-west of Iran
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo
Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Post-Bacille Calmette–Guerin surveillance for non-muscle invasive bladder cancer: do random biopsies offer an advantage?
Durch Bacillus Calmette-Guerin induzierte Tuberkulose
Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Bacille Calmette-Guérin Supply Disruption Emphasizes the Importance of Stewardship
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Bekämpfung der Tuberkulose: Schutzimpfung mit Bacillus Calmette-Guérin (BCG)
Immunologic aspects of patients with disseminated bacille Calmette-Guerin disease in north-west of Iran
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo
Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Post-Bacille Calmette–Guerin surveillance for non-muscle invasive bladder cancer: do random biopsies offer an advantage?
Durch Bacillus Calmette-Guerin induzierte Tuberkulose
Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
Bacille Calmette-Guérin Supply Disruption Emphasizes the Importance of Stewardship
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Bekämpfung der Tuberkulose: Schutzimpfung mit Bacillus Calmette-Guérin (BCG)